Concurrent Radiosurgery and Systemic Therapies for Melanoma Brain Metastases: A Systematic Review

Bradley D. Weaver ¹, James R. Goodman ², Randy Jensen ³

¹. Oncology, University of Utah, Salt Lake City, USA  ². Anesthesiology, Oregon Health & Science University, Portland, USA  ³. Neurosurgery, University of Utah, Salt Lake City, USA

☐ Corresponding author: Randy Jensen, randy.jensen@hsc.utah.edu

Abstract

Intracranial metastatic melanoma is a major challenge for neuro-oncological teams. Historically, treatment has focused on surgical or radiosurgical treatment of appropriate lesions, mostly for palliative purposes. Immunotherapies and other targeted therapies (BRAF/mitogen-activated protein kinase kinase inhibitors (BRAFi/MEKi)) are mainstays of advanced melanoma therapy, yet the optimal timing and synergistic properties of concurrent combinations of these systemic therapies and stereotactic radiosurgery (SRS) are poorly understood. We performed a systematic review of the MEDLINE and Scopus databases focused on outcomes after therapy using SRS and either immunotherapies or targeted therapies in an effort to define the optimal timing. We defined concurrent therapy as SRS within three months of treatment with any systemic therapy. End points included local control, distant control, overall survival, and toxicities. We identified five retrospective cohort studies from the literature. These studies found that concurrent SRS plus immunotherapy or BRAFi/MEKi is well tolerated by most patients and generally improved local control, distant control, overall survival, and toxicities. We identified five retrospective cohort studies from the literature. These studies found that concurrent SRS plus immunotherapy or BRAFi/MEKi is well tolerated by most patients and generally improved local control, distant control, overall survival, and toxicities. Importantly, no significant increases in toxicities were noted with concurrent therapy. Combining concurrent SRS with immunotherapy or BRAFi/MEKi may offer important advances for patients with intracranial metastatic melanoma. To address interstudy heterogeneity, we propose reporting two major time intervals defining "concurrent treatment": concurrent-SRS (≤4 weeks) and peri-SRS (≤3 months). Future large-scale, prospective trials considering truly concurrent SRS therapies with systemic therapies are desperately needed.

Categories: Radiation Oncology, Oncology, Neurosurgery

Keywords: melanoma, stereotactic radiosurgery, targeted therapy, immunotherapy, brain metastases

Introduction And Background

Intracranial metastatic melanoma is a devastating and common occurrence in patients with advanced melanoma. As of 2011, more than 40% of patients with metastatic melanoma experienced brain metastasis, and this number is increasing [1-2]. Stereotactic radiosurgery (SRS) is a safe and effective modality for treating many types of primary and metastatic brain tumors and is commonly used for the treatment of melanoma brain metastasis. BRAF-V600E is the most common activating mutation found in melanoma. After the molecular diagnosis is established, targeted therapies (TTs) such as BRAF/mitogen-activated protein (MAP) kinase kinase (MEK) inhibitors (BRAFi/MEKi), which block the activated MAP-kinase cascade are employed [3]. Immunotherapeutics (IMTs) such as ipilimumab (anti-CTLA4 [cytotoxic T-lymphocyte associated protein 4] therapy) have yielded improved overall survival from metastatic melanoma (two large, phase III trials), and along with nivolumab/pembrolizumab (anti-PD1 [programmed cell death protein 1] therapy), comprise the cornerstone of current
melanoma immunotherapy [4-5]. Recently, phase II trials have begun investigating the effectiveness of IMTs with and without SRS [NCT02085070; NCT02374242; NCT02460068; NCT02320058]. Importantly, the optimal timing of combination systemic therapy and SRS is yet to be defined, particularly for IMTs, and preclinical studies suggest that concurrent therapy may be superior to staggered drug and SRS administration [6]. We undertook a systematic review of studies involving a window of concurrent systemic therapy within three months of SRS treatment, defined as administration of IMT or TT within three months of SRS, in an effort to better define the optimal timing.

**Review**

**Database review**

Two separate reviewers performed Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA)-based systematic reviews of both Scopus and MEDLINE databases (October 2018) using "stereotactic radiosurgery" and "melanoma" as keywords. Articles were included if they examined the treatment of intracranial metastatic melanoma with SRS and BRAFi/MEKi inhibitors or immunotherapeutic checkpoint inhibitors (i.e., anti-PD1 and anti-CTLA4 monoclonal antibodies). Studies were included if they reported ≤30% of patients previously, or concurrently, treated with whole-brain radiotherapy. Critically, studies were included only if they described concurrent combinations of SRS and systemic therapies (i.e., systemic therapy within a three-month window before or after SRS treatment) (Table 1). Endpoints of interest included overall survival, local control, distant control, and treatment toxicities.

After a systematic review of the literature, five articles were included for qualitative analysis (Figure 1). Hazard ratios (HRs) reported were transformed from failure to control, if necessary, using 1/HR. If a study presented both univariate and multivariate analyses of an outcome measure, the multivariate analysis was included in our qualitative assessment.

---

**FIGURE 1: Diagram of PRISMA workflow representing search strategy, results, and inclusion criteria**

Inclusion Criteria
1. Intracranial metastatic melanoma
2. Stereotactic radiosurgery (SRS) as treatment
3. Immunotherapy or other targeted systemic therapy used
4. Less than 30% pts treated with whole-brain radiotherapy
5. SRS within 3 months of systemic therapy
6. Study must be patient centered, sufficiently powered, and relatively free of bias
7. Study must report one or more of the following outcomes: Local control, distant control, overall survival, radiation necrosis (other toxicities)
Studies identified

The five retrospective cohort studies that met our inclusion criteria all provided only low-quality evidence with heterogeneous outcomes (Table 1; GRADE (Grading of Recommendations Assessment, Development, and Evaluation) criteria); therefore, a meta-analysis of the data was not possible [7-11]. A major source of heterogeneity in all studies of SRS and systemic therapies is the definition of ‘concurrent’ therapy. To address this issue, we propose assessment during two key intervals: a four-week interval (concurrent therapy) and a three-month window (peri-SRS therapy).

<table>
<thead>
<tr>
<th>Article</th>
<th>Number of patients</th>
<th>Total no. of brain mets</th>
<th>Type of radiosurgery</th>
<th>Type(s) of targeted and immunotherapies</th>
<th>Concurrent treatment definition</th>
<th>Patients (% of total) who had WBRT</th>
<th>Endpoints measured</th>
<th>Statistics used</th>
<th>GRADE quality and bias assessment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ahmed et al. (2016)</td>
<td>96</td>
<td>314</td>
<td>Single-fraction BrainLab Novalis Classic LINAC</td>
<td>Anti-PD1/anti-CTLA4 = nivolumab/ pembrolizumab, ipilimumab; BRAFi/MEKi = dabrafenib/ trametinib, vemurafenib</td>
<td>3 months; BRAF/ MEK inhibitors held for 2–3 days before/after SRS</td>
<td>Not reported</td>
<td>Distant brain control, local control, progression-free survival, overall survival, neurotoxicity</td>
<td>Kruskal–Wallis, Pearson’s Chi-squared, Fisher’s exact tests. Kaplan Meier and log-rank tests. Cox prop hazards for hazard ratios.</td>
<td>LOW: small, retrospective cohort study. No downgrade required.</td>
</tr>
</tbody>
</table>
TABLE 1: Details of the retrospective cohort studies included in this review

<table>
<thead>
<tr>
<th>Study</th>
<th>Sample Size</th>
<th>Outcome Measures</th>
<th>Immunotherapy</th>
<th>Radiation Therapy</th>
<th>Study Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yusuf et al. (2017)</td>
<td>51</td>
<td>Failure, local failure, percent lesion regression, overall survival, neurotoxicity</td>
<td>Anti-PD1/anti-CTLA4 = ipilimumab/pembrolizumab</td>
<td>CyberKnife/Varian Trilogy LINAC</td>
<td>Low: small, retrospective cohort study. No downgrade required.</td>
</tr>
</tbody>
</table>

Concurrent therapy was generally favored for all reported outcomes. Possibly, the largest effect was on distant brain control combining IMT+SRS (HRs ≥2 for distant control in all but one case; Figure 2). Local control favored concurrent therapy, but this trend was obscured by unexpected differences in HRs for similar patient populations (Figure 2) [9,11]. Overall survival with concurrent IMT+SRS was also improved. Only Acharya et al. found a statistically insignificant decrease in HR for overall survival in patients receiving concurrent IMT and SRS (Figure 2) [7]. There was no significant difference in toxicities between the SRS only and the SRS + IMT treatment groups (Table 2).

Results of Concurrent Immunotherapy and SRS

Concurrent therapy was generally favored for all reported outcomes. Possibly, the largest effect was on distant brain control combining IMT+SRS (HRs ≥2 for distant control in all but one case; Figure 2). Local control favored concurrent therapy, but this trend was obscured by unexpected differences in HRs for similar patient populations (Figure 2) [9,11]. Overall survival with concurrent IMT+SRS was also improved. Only Acharya et al. found a statistically insignificant decrease in HR for overall survival in patients receiving concurrent IMT and SRS (Figure 2) [7]. There was no significant difference in toxicities between the SRS only and the SRS + IMT treatment groups (Table 2).

FIGURE 2: Efficacy of concurrent immunotherapy and SRS for melanoma brain metastases
Regression or control of lesions outside of the initial radiation field, called the abscopal effect, may drive favorable outcomes for distant brain tumors in patients treated with concurrent IMT+SRS [12-14]. The abscopal effect is an immune system-mediated effect that requires T-cell effector function on tumor-associated neoantigens (TAAs) and immune-enhancing cytokine release in the tumor microenvironment. This may synergize with checkpoint inhibitors, releasing the brakes on antitumor immunity (Figure 3) [15-17]. The reactivation of innate immune-sensing and interferon responses in tumor cells, which is critical for antitumor immunity, is attributed to the expression of endogenous retroviral sequences and other genomic 'dark matter' after epigenetic therapies [18,19-21]. Combining epigenetic, stereotactic radiosurgical, and immune-checkpoint therapies may hold great promise for patients with
melanoma brain metastasis.

FIGURE 3: Model of increased abscopal response in combination immunotherapy and radiosurgery

1) Irradiation of tumor causes the release of TAAs. 2) Cytotoxic T-cell activation by APCs. 3) Immunotherapy facilitates T-cell activation (anti-CTLA4) and prevents immune checkpoint activation (anti-PD1). 4) Increased abscopal effect and local tumor responses.

Results of BRAFi/MEKi and Stereotactic Radiosurgery

Inhibitors of the MAP-kinase pathway have become a mainstay of melanoma treatment, particularly in the setting of activating BRAF mutations. Importantly, patients treated with targeted therapies after molecular diagnosis have significantly better progression-free and overall survival than patients treated with dacarbazine or placebo [22-25]. There is little information regarding the optimal timing of targeted therapy dosage relative to SRS, but many oncological teams withhold targeted therapies for 3-5 days surrounding SRS treatment. Studies that report the efficacy of SRS and targeted therapies are summarized in Table 4, including reason for exclusion from our systematic review [26-30]. Improved brain tumor control and overall survival evident in concurrent or post-SRS (Figure 4; Table 3) BRAFi/MEKi may reflect increased accessibility of these therapies to the brain tumor environment after SRS, yet concurrent vemurafenib or dabrafenib and SRS has been reported to increase risk for radiation necrosis and Grade ≥3 adverse events, especially skin toxicities [30-32]. Of interest, there were no significant differences in toxicities in patients receiving concurrent BRAFi/MEKi+SRS versus SRS alone, indicating that a small pause directly surrounding SRS may be sufficient to ensure patient safety (Table 3).
FIGURE 4: Efficacy of concurrent targeted therapy and SRS for melanoma brain metastases

BRAFi, BRAF inhibitor therapy; MEKi, MEK inhibitor therapy; TT, targeted therapy; SRS, stereotactic radiosurgery
<table>
<thead>
<tr>
<th>Study</th>
<th>Overall Survival</th>
<th>Local Control</th>
<th>Distant Control</th>
<th>Toxicities</th>
<th>Comparator</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acharya et al. (2017)</td>
<td>NR</td>
<td>1.96 (0.99–3.45)* p=0.054</td>
<td>0.85 (0.54–1.12)*; BRAFi/MEKi vs BRAFi alone p=0.011</td>
<td>Toxicities noted in all group; no differences</td>
<td>SRS alone with multiple subgroup analyses</td>
</tr>
<tr>
<td>Ahmed et al. (2016)</td>
<td>BRAFi/MEKi 2.4 (1.1–5.3) p = 0.02; BRAFi 1.79 (0.89–3.28) **</td>
<td>BRAFi/MEKi 2.82 (0.85–12.8) p=0.09; BRAFi 2 (0.72–6.0) p = 0.18 **</td>
<td>BRAFi/MEKi 2.1 (1.1–4.4) p = 0.03; BRAFi alone 1.4 (0.75–2.9) p = 0.27</td>
<td>Toxicities noted in all group; no differences</td>
<td>SRS alone; chemotherapy controlled</td>
</tr>
<tr>
<td>Diao et al. (2018)</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>Diao et al. (2018)</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>Yusuf et al. (2017)</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
</tr>
</tbody>
</table>

**TABLE 3: Studies considering treatment efficacy of SRS and targeted therapy**

SRS, stereotactic radiosurgery; NR, not reported in study outcomes; BRAFi, BRAF inhibitor; MEKi, MEK inhibitor

*Converted from failure to control; **Chemotherapy controlled

[7-11]
<table>
<thead>
<tr>
<th>Study</th>
<th>Outcome</th>
<th>Reason for Exclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kotecha et al., (2017)</td>
<td>Improved LC, OS in concurrent SRS</td>
<td>High number (&gt;30%) WBRT</td>
</tr>
<tr>
<td>Mastorakos et al., (2019)</td>
<td>Improved OS initiating inhibitor after SRS</td>
<td>No timing details, no HRs/statistics provided</td>
</tr>
<tr>
<td>Wolf et al., (2016)</td>
<td>Improved OS in concurrent or after SRS strategies</td>
<td>No timing details, no HRs/statistics provided</td>
</tr>
<tr>
<td>Xu et al., (2017)</td>
<td>Improved LC with any BRAFi + SRS</td>
<td>Small sample size, heterogeneous timing. No HRs/statistics provided</td>
</tr>
<tr>
<td>Hecht et al., (2018)</td>
<td>Improved OS in an interrupted therapy group</td>
<td>High number (&gt;30%) WBRT</td>
</tr>
</tbody>
</table>

**TABLE 4: Excluded studies considering SRS + BRAFi/MEKi therapies**

SRS, stereotactic radiosurgery; LC, local control; OS, overall survival; WBRT, whole-brain radiation therapy; HR, hazard ratio

[27-30,33]

**Conclusions**

Five studies in the literature explore concurrent timing of stereotactic radiosurgery and immunotherapy or targeted therapies for the treatment of intracranial metastatic melanomas. Additional temporally specific studies are needed, but more vital is the need for well-designed prospective trials, several of which are under way [NCT02085070; NCT02374242; NCT02460068; NCT02320058]. Future studies should report outcomes based on a four-week window (concurrent SRS) or a three-month window (peri-SRS).

**Additional Information**

**Disclosures**

**Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

**Acknowledgements**

We thank Kristin Kraus, MSc, for editorial assistance.

**References**


6. Dovedi S, Illidge T: The antitumor immune response generated by fractionated radiation therapy may be limited by tumor cell adaptive resistance and can be circumvented by PD-L1 blockade. Oncoimmunology. 2015, 4;1016709. 10.1080/2162402X.2015.1016709


22. Chapman PB, Hauschild A, Robert C, et al.: Improved survival with vemurafenib in melanoma...